Logo image of DRRX

DURECT CORPORATION (DRRX) Stock Price, Quote, News and Overview

NASDAQ:DRRX - Nasdaq - US2666055007 - Common Stock - Currency: USD

0.6101  -0.06 (-8.89%)

After market: 0.6887 +0.08 (+12.88%)

DRRX Quote, Performance and Key Statistics

DURECT CORPORATION

NASDAQ:DRRX (4/28/2025, 6:22:32 PM)

After market: 0.6887 +0.08 (+12.88%)

0.6101

-0.06 (-8.89%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High1.88
52 Week Low0.56
Market Cap18.94M
Shares31.04M
Float27.56M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-19 2025-05-19
IPO09-28 2000-09-28


DRRX short term performance overview.The bars show the price performance of DRRX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40 -50

DRRX long term performance overview.The bars show the price performance of DRRX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of DRRX is 0.6101 USD. In the past month the price decreased by -23.74%. In the past year, price decreased by -47.41%.

DURECT CORPORATION / DRRX Daily stock chart

DRRX Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 67.48 831.66B
JNJ JOHNSON & JOHNSON 15.46 374.37B
NVO NOVO-NORDISK A/S-SPONS ADR 18.15 277.97B
NVS NOVARTIS AG-SPONSORED ADR 14.19 222.45B
AZN ASTRAZENECA PLC-SPONS ADR 16.85 216.81B
MRK MERCK & CO. INC. 10.68 209.34B
PFE PFIZER INC 7.41 130.73B
SNY SANOFI-ADR 13.7 129.16B
BMY BRISTOL-MYERS SQUIBB CO 6.6 98.60B
GSK GSK PLC-SPON ADR 8.75 77.12B
ZTS ZOETIS INC 25.94 68.50B
TAK TAKEDA PHARMACEUTIC-SP ADR 32.96 47.71B

About DRRX

Company Profile

DRRX logo image DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. The company is headquartered in Cupertino, California and currently employs 21 full-time employees. The company went IPO on 2000-09-28. The firm is engaged in the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury. Its lead drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in alcoholic hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which the FDA has granted a Fast Track and a Therapy designation, and metabolic dysfunction-associated steatohepatitis (MASH) is also being explored. Its commercial pharmaceutical product includes POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology. The company has developed a proprietary drug product for the treatment of ADHD called Methydur.

Company Info

DURECT CORPORATION

10240 Bubb Road

Cupertino CALIFORNIA 95014 US

CEO: James E. Brown

Employees: 48

Company Website: https://www.durect.com/

Investor Relations: https://investors.durect.com

Phone: 14087771417

DURECT CORPORATION / DRRX FAQ

What is the stock price of DURECT CORPORATION today?

The current stock price of DRRX is 0.6101 USD. The price decreased by -8.89% in the last trading session.


What is the ticker symbol for DURECT CORPORATION stock?

The exchange symbol of DURECT CORPORATION is DRRX and it is listed on the Nasdaq exchange.


On which exchange is DRRX stock listed?

DRRX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for DURECT CORPORATION stock?

9 analysts have analysed DRRX and the average price target is 6.89 USD. This implies a price increase of 1028.5% is expected in the next year compared to the current price of 0.6101. Check the DURECT CORPORATION stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is DURECT CORPORATION worth?

DURECT CORPORATION (DRRX) has a market capitalization of 18.94M USD. This makes DRRX a Nano Cap stock.


How many employees does DURECT CORPORATION have?

DURECT CORPORATION (DRRX) currently has 48 employees.


What are the support and resistance levels for DURECT CORPORATION (DRRX) stock?

DURECT CORPORATION (DRRX) has a resistance level at 0.74. Check the full technical report for a detailed analysis of DRRX support and resistance levels.


Is DURECT CORPORATION (DRRX) expected to grow?

The Revenue of DURECT CORPORATION (DRRX) is expected to decline by -94.07% in the next year. Check the estimates tab for more information on the DRRX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy DURECT CORPORATION (DRRX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does DURECT CORPORATION (DRRX) stock pay dividends?

DRRX does not pay a dividend.


When does DURECT CORPORATION (DRRX) report earnings?

DURECT CORPORATION (DRRX) will report earnings on 2025-05-19.


What is the Price/Earnings (PE) ratio of DURECT CORPORATION (DRRX)?

DURECT CORPORATION (DRRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.27).


What is the Short Interest ratio of DURECT CORPORATION (DRRX) stock?

The outstanding short interest for DURECT CORPORATION (DRRX) is 2.53% of its float. Check the ownership tab for more information on the DRRX short interest.


DRRX Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

DRRX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to DRRX. DRRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

DRRX Financial Highlights

Over the last trailing twelve months DRRX reported a non-GAAP Earnings per Share(EPS) of -0.27. The EPS increased by 76.11% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -45.36%
ROE -91.16%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%340%
Sales Q2Q%-54.59%
EPS 1Y (TTM)76.11%
Revenue 1Y (TTM)-25.64%

DRRX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to DRRX. The Buy consensus is the average rating of analysts ratings from 9 analysts.

For the next year, analysts expect an EPS growth of -109.04% and a revenue growth -94.07% for DRRX


Ownership
Inst Owners22.18%
Ins Owners10.78%
Short Float %2.53%
Short Ratio15.34
Analysts
Analysts82.22
Price Target6.89 (1029.32%)
EPS Next Y-109.04%
Revenue Next Year-94.07%